US › Healthcare

Artiva Biotherapeutics, Inc. Common Stock (ARTV)

US · Healthcare · Biotechnology

$11.07+2.88%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-23.5M
Profit YoY
-15.8%
EPS
$-0.95
EPS estimate
$-0.88

EPS came in at -0.95 against a street estimate of -0.88 — a miss of 8.0%.

Key statistics

Market cap
$522.8M
Forward P/E
0.0
P/B
5.58
Book value
$3.55
EPS (TTM)
$-3.55
52-week high
$14.53
52-week low
$2.22
50-day MA
$8.94
200-day MA
$6.48
Beta
2.18

Analyst view

Analysts rate Artiva Biotherapeutics, Inc. Common Stock a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $35.80.

Shareholding

Insiders
14.14%
Institutions
52.69%

Largest institutional holders

FundStake
RA Capital Management, LLC20.28%
5AM Venture Management, LLC4.84%
VR Adviser, LLC3.31%
venBio Partners LLC1.09%
Franklin Resources Inc1.07%
Revelation Capital Management, LLC0.62%
Vanguard Group Inc0.51%
BlackRock Inc0.44%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Artiva Biotherapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.